TABLE 1.
Effect size estimates by each method
| Disease | No. case | No. control | IVW | MR‐Egger | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta | SE | OR (95% CI) | P | Beta | SE | OR (95% CI) | P | Intercept (95% CI) | P | |||
| Ovarian cancer | 647 | 39 556 | 0.409 | 0.265 | 1.12 (0.97 to 1.29) | .12 | 1.093 | 0.702 | 1.35 (0.93 to 1.96) | .12 | −0.021 (−0.059 to 0.018) | .30 |
| Uterine endometrial cancer | 909 | 39 556 | 0.735 | 0.223 | 1.22 (1.08 to 1.38) | .0010 | 1.625 | 0.583 | 1.56 (1.14 to 2.12) | .0068 | −0.027 (−0.059 to 0.0050) | .10 |
| Uterine cervical cancer | 538 | 39 556 | 0.062 | 0.290 | 1.02 (0.87 to 1.19) | .83 | 0.157 | 0.759 | 1.04 (0.70 to 1.56) | .84 | −0.0029 (−0.045 to 0.039) | .89 |
| Uterine fibroid | 5236 | 39 556 | 0.081 | 0.131 | 1.02 (0.95 to 1.10) | .54 | 0.054 | 0.345 | 1.01 (0.84 to 1.22) | .88 | 0.00080 (−0.018 to 0.020) | .93 |
| Endometriosis | 645 | 39 556 | −0.062 | 0.286 | 0.98 (0.84 to 1.15) | .83 | −0.262 | 0.767 | 0.93 (0.62 to 1.40) | .73 | 0.0060 (−0.036 to 0.048) | .78 |
Sample sizes for each GWAS and causal effect estimates of BMI on each gynecologic disease are shown.
Beta and standard error (SE) is based on per standard deviation (SD) increase of BMI, and OR is based on per 1 kg/m2 increase of BMI.
BMI GWAS was conducted among the independent 105 534 subjects with standardized phenotypic values.
BMI, body mass index; CI, confidence interval; GWAS, genome‐wide association study; IVW, inverse variance‐weighted; OR, odds ratio.